Bupivacaine Hydrochloride Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Bupivacaine Hydrochloride Injection (injection) from Hospira, Inc., A Pfizer Company with status No longer listed by FDA. The shortage was first posted on Feb 20, 2018. Reported reason: Discontinuation of the manufacture of the drug
Shortage details
- Status
- No longer listed by FDA
- Company
- Hospira, Inc., A Pfizer Company
- Package NDC
- 0409-1159-10
- Dosage Form
- Injection
- Presentation
- Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)
- Initial Posting
- Feb 20, 2018
Reason
Discontinuation of the manufacture of the drug